VivoSeq
Oncology

Gastroesophageal Adenocarcinoma

17

Pipeline Programs↗

5

Active Trials↗

8

Companies Involved↗

Gastroesophageal Adenocarcinoma is an emerging landscape with 17 programs across 8 companies. The most active players are AstraZeneca, Bristol-Myers Squibb, Jazz Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

5 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2Arcus Biosciences logo

Arcus Biosciences

1 program

Phase 2Merck & Co. logo

Merck & Co.

4 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

14programs
Small molecule750%
Monoclonal antibody536%
Antibody–drug conjugate214%

Modality classified for 83% of 18 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Not yet recruiting1 · 20%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07069712·100 enrolled
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial: A Phase II Randomized Open-Label Trial of Perioperative Simvastatin Plus Standard-of-Care Systemic Therapy in Gastroesophageal Adenocarcinoma
Not yet recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT07625930·184 enrolled
A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT06445972·210 enrolled
- ZANGEA - Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT07176312·80 enrolled
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04021108·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)